News and Press

News

BioMotiv Expands with a New Office in Philadelphia

On Wednesday, April 25, BioMotiv colleagues and friends gathered to celebrate the opening of a new Philadelphia office located in The Innovation Hub, a collaborative life sciences space managed by Militia Hill Ventures.

BioMotiv at 2018 MassBio Annual Meeting

Our Chief Business Officer, Terry Vance, joined a panel at MassBio’s 2018 Annual Meeting that drew over 400 industry leaders. The panel provided insights into family office investments in biotech during the two day event that focused on the most innovative...

BioMotiv Featured in Drug Discovery World

“Emerging drug discovery alliance models” discusses the current environment for early-stage drug discovery and development, highlights challenges to success, and suggests the need for allied partnerships in the drug development sphere using BioMotiv as one such model....

BioMotiv at AUTM 2018 Annual Meeting

Our colleague, Kaushik Ghosal, will be joining the Association of University Technology Managers (AUTM) 2018 Annual Meeting as a panelist at the "Creative Models to De-Risk Early Stage BioMedical Technology Development" session on February 21. He will present...

Social Finance Forum: Navigating Impact in Health

TORONTO, November 2017 – Baiju Shah joined international leaders in the social finance and impact investing space for the 10th Annual Social Finance Forum. He represented BioMotiv on the Navigating Impact in Health panel to discuss innovative approaches to the drug...

Press Releases

OptiKira Achieves Significant Proof-of-Principle Milestone

OptiKira, LLC, a privately-held biotechnology startup developing drugs that inhibit the unfolded protein response (UPR) with applications in a variety of diseases, including retinitis pigmentosa, type I diabetes, idiopathic pulmonary fibrosis (IPF), amyotrophic lateral sclerosis (ALS), and immuno-oncology announced today that it achieved a significant proof-of-principle milestone.

Allinaire Awarded Grant for Novel Pulmonary Treatment

CLEVELAND and INDIANAPOLIS, February 12, 2018 - Allinaire Therapeutics has been awarded a Phase I Small Business Technology Transfer grant from the National Heart, Lung and Blood Institute. Allinaire's aim is to support the advancement of new drug therapies for...

2018 Harrington Scholar-Innovators Selected

CLEVELAND, OHIO, January 18 - Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, part of The Harrington Project for Discovery & Development, has announced its 2018 Harrington Scholar-Innovator Award recipients.  The 10 physician-scientists...

Koutif Therapeutics Launched to Treat Inflammatory Diseases

CLEVELAND AND PITTSBURGH, September 21, 2017 -  BioMotiv, a drug development accelerator, and the University of Pittsburgh announced the launch of Koutif Therapeutics, which is developing an inhibitor of an E3 ligase (Fbxo3) to treat inflammatory conditions such as...

Allinaire Awarded $1.9M in Grant Funding

CLEVELAND and INDIANAPOLIS, September 19, 2017 - Allinaire Therapeutics has been awarded a $1,670,000 Phase II SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) and a $213,000 Discovery Award from the Department of Defense (DOD). The funding will...

Nature Features Sujana’s Technology

CLEVELAND, June 5, 2017 - Nature Communications has published the research of Daniel I. Simon, M.D.; Edward Plow, Ph.D.; and Yunmei Wang, Ph.D. - Founders of Sujana Biotech - which describes a novel target for thrombotic disorders that does not effect hemostasis...

2017 Harrington Prize for Innovation in Medicine Awarded

CLEVELAND, OH - March 15, 2017 The Harrington Discovery Institute and The American Society for Clinical Investigation are pleased to announce that the 2017 Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD of Mt. Sinai...

OptiKira Receives Significant Grant from ALS Association

CLEVELAND, OH - February 9, 2017 OptiKira has been awarded a $498,500 grant to support the development of their platform technology for the treatment of ALS (Lou Gehrig's disease).  The company's technology prevents progressive cell death and is being developed for a...